Omega-3 lowers inflammation, blood pressure in obese adults
Cardiovascular disease, or CVD, is a leading cause of death worldwide, and diet strongly influences risk. The American Heart Association recommends reducing saturated fat and increasing polyunsaturated fatty acids, or PUFA, intake, which may cut CVD risk by up to 30%. PUFAs include omega-3 and omega-6, but their direct effects on CVD-related inflammation have not been well compared.
In a recent study, published in the Journal of Lipid Research, Elise Grytten of Haukeland University Hospital and colleagues compared omega-3, or fish oil, and omega-6, or safflower oil, supplements on CVD risk markers. Participants were overweight adults aged 30–70 with abdominal obesity. They received either omega-3 supplements (rich in eicosapentaenoic, or EPA, and docosahexaenoic, or DHA, acids) or omega-6 supplements (rich in linoleic acid) in randomized seven-week sequences. Omega-3 supplements reduced proinflammatory chemokines such as CCL5 and CCL4, suggesting these anti-inflammatory effects could lower CVD risk. Transcriptomic analysis showed overlapping changes in 75 genes across both groups. However, omega-6s’ anti-inflammatory benefits depended on sufficient omega-3 intake. Furthermore, omega-3 lowered blood pressure in participants without hypertension, while omega-6 increased it. Overall, the findings suggest that high-quality omega-3– and omega-6–rich oils may lower the risk of abdominal obesity and cardiometabolic disease. Also, supplementation of omega-6, in contrast to omega-6, appeared to increase adipose inflammation, with unknown clinical relevance.
Despite limitations — including possible carryover effects, unequal supplement doses and small sample size — the authors believe their findings provide new insight into how PUFAs affect adipose inflammation. In the future, they plan to study how omega-6 alters linoleic acid–derived metabolites.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Bacteriophage protein could make queso fresco safer
Researchers characterized the structure and function of PlyP100, a bacteriophage protein that shows promise as a food-safe antimicrobial for preventing Listeria monocytogenes growth in fresh cheeses.
Building the blueprint to block HIV
Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7–10, in Maryland.
Gut microbes hijack cancer pathway in high-fat diets
Researchers at the Feinstein Institutes for Medical Research found that a high-fat diet increases ammonia-producing bacteria in the gut microbiome of mice, which in turn disrupts TGF-β signaling and promotes colorectal cancer.
Mapping fentanyl’s cellular footprint
Using a new imaging method, researchers at State University of New York at Buffalo traced fentanyl’s effects inside brain immune cells, revealing how the drug alters lipid droplets, pointing to new paths for addiction diagnostics.
Designing life’s building blocks with AI
Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.
Cholesterol as a novel biomarker for Fragile X syndrome
Researchers in Quebec identified lower levels of a brain cholesterol metabolite, 24-hydroxycholesterol, in patients with fragile X syndrome, a finding that could provide a simple blood-based biomarker for understanding and managing the condition.